爱尔兰药物经济学评估的最新进展。 - Suppr

Suppr

超能文献

Recent developments in pharmacoeconomic evaluation in Ireland.

作者信息

Tilson Lesley, Barry Michael

出版信息

Expert Rev Pharmacoecon Outcomes Res. 2010 Jun;10(3):221-4. doi: 10.1586/erp.10.33.

DOI:10.1586/erp.10.33

PMID:20545585

Abstract

摘要

相似文献

Recent developments in pharmacoeconomic evaluation in Ireland.爱尔兰药物经济学评估的最新进展。

Expert Rev Pharmacoecon Outcomes Res. 2010 Jun;10(3):221-4. doi: 10.1586/erp.10.33.

Public drug expenditure in the Republic of Ireland.爱尔兰共和国的公共药物支出。

Expert Rev Pharmacoecon Outcomes Res. 2010 Jun;10(3):239-45. doi: 10.1586/erp.10.23.

Drug expenditure in Ireland 1997-2007.1997年至2007年爱尔兰的药品支出。

Ir Med J. 2008 Nov-Dec;101(10):299-302.

Pharmacoeconomic evaluation in Ireland: a review of the process.爱尔兰的药物经济学评价：过程回顾。

Pharmacoeconomics. 2010;28(4):307-22. doi: 10.2165/11318790-000000000-00000.

Captive markets.垄断市场

Minn Med. 2008 Nov;91(11):12-3.

Prescription drug costs easier to swallow.处方药成本更易承受。

State Legis. 2010 Apr;36(4):10.

Pharmaceutical economy and the economic assessment of drugs in France.法国的药物经济学与药物经济评估

Soc Sci Med. 1997 Aug;45(4):635-43. doi: 10.1016/s0277-9536(96)00402-9.

More blockbusters on the way. Pharmaceutical spending and the impact of pipeline drugs.更多重磅药物即将问世。医药支出与在研药物的影响。

Mich Health Hosp. 2001 Sep-Oct;37(5):20-3.

The true cost and benefit of medication reduction.药物减量的真实成本与效益。

Del Med J. 2009 Apr;81(4):163-4.

[Economic drug prescription].

Ugeskr Laeger. 2003 Dec 8;165(50):4871-2.

引用本文的文献

Pharmacoepidemiology resources in Ireland-an introduction to pharmacy claims data.爱尔兰的药物流行病学资源——药房理赔数据介绍

Eur J Clin Pharmacol. 2017 Nov;73(11):1449-1455. doi: 10.1007/s00228-017-2310-7. Epub 2017 Aug 17.

The Irish Cost-Effectiveness Threshold: Does it Support Rational Rationing or Might it Lead to Unintended Harm to Ireland's Health System?爱尔兰的成本效益阈值：它是支持合理配给，还是可能对爱尔兰的医疗系统造成意想不到的损害？

Pharmacoeconomics. 2016 Jan;34(1):5-11. doi: 10.1007/s40273-015-0336-1.

The quality of economic evaluations of ultra-orphan drugs in Europe - a systematic review.欧洲超罕见病药物经济评估的质量——一项系统评价

Orphanet J Rare Dis. 2015 Jul 30;10:92. doi: 10.1186/s13023-015-0305-y.

A systematic review of cost-sharing strategies used within publicly-funded drug plans in member countries of the organisation for economic co-operation and development.对经济合作与发展组织成员国公共资助药品计划中使用的费用分担策略的系统评价。

PLoS One. 2014 Mar 11;9(3):e90434. doi: 10.1371/journal.pone.0090434. eCollection 2014.

Optimizing pharmacotherapy in older patients: a European perspective.老年患者药物治疗的优化：欧洲视角

Drugs Aging. 2012 Jun 1;29(6):423-5. doi: 10.2165/11630990-000000000-00000.

Role of centralized review processes for making reimbursement decisions on new health technologies in Europe.集中审查程序在欧洲新医疗技术报销决策中的作用。

Clinicoecon Outcomes Res. 2011;3:117-86. doi: 10.2147/CEOR.S14407. Epub 2011 Aug 30.

Valorising and creating access to innovative medicines in the European union.在欧盟实现创新药物的增值和可及性。

Front Pharmacol. 2011 Oct 11;2:57. doi: 10.3389/fphar.2011.00057. eCollection 2011.

How to assess the value of medicines?如何评估药品的价值？

Front Pharmacol. 2010 Sep 7;1:115. doi: 10.3389/fphar.2010.00115. eCollection 2010.

Use of economic evaluation in decision making: evidence and recommendations for improvement.经济评估在决策中的应用：证据与改进建议。

Drugs. 2010 Oct 22;70(15):1917-26. doi: 10.2165/11538120-000000000-00000.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验